The recent announcement of Sanofi agreeing to help produce Pfizer's COVID-19 vaccine could represent biopharma's entry into a period of unprecedented collaboration.

Rob Wright, chief editor of Life Science Leader, shares thoughts on attending the 39th Annual J.P. Morgan Healthcare Conference (JPM) which was 100% virtual this year.

Life Science Leader's Rob Wright reviews five things that went right in 2020.

“I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.

Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch. 

New Year’s is not just a time of celebration, but a point at which we step out of the day-to-day to reflect on how we did — and resolve to do better.

2020 was the year that everything changed, including this year’s annual CEO outlook article. Normally fully focused on the future, this year’s version contains some reflection, which seems appropriate in our new norm.

We invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations.

As we’ve done previously, this year we posed many questions to lots of executives across a variety of life science industry disciplines, and here you will gain perspectives on what to expect on biosimilars to outsourcing, and everything in between.